Worth reading
70In focus
Scored from 3 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
56
¥ millions (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ended June 2021 (full year)7 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,124 million+0.5%
Operating profit¥39 million
Ordinary income¥59 million
Net income¥58 million
Full-year earnings forecast
Net Sales
¥1,200 million
Operating profit
¥100 million
Ordinary income
¥100 million
Profit attributable to owners of the parent
¥100 million
Earnings per share
¥16.95
What the company explained in this material
New initiatives
- Expand and promote new analysis services
- Launch the healthcare solutions development business
- Research and development aimed at commercializing a mental health-related business
- Close HMT Europe by the end of 2021 and consolidate European operations under HMT America
Key KPIsA metric the company considers important as a management benchmark.
- Metabolomics business orders received¥996 millionYear on year against the same period last year-15%
- Next year's sales budget¥1,200 million
- Number of metabolomics-related papers9,000 papers or more
- Number of papers in which the company was involved600 papers or more
- Cumulative number of tests (projects)7,000 Cases or more
- Domestic share of the metabolomics market70 Approximately %
Segment results
Metabolomics business
Net Sales
¥1,119 million
Operating profit
¥423 million
Biomarker business
Net Sales
¥4 million
Operating profit
¥-70 million
Corporate and eliminations
Operating profit
¥-313 million
Medium-term management plan targets
Net Sales
¥1,600 million
Target fiscal yearFY2025
Profit attributable to owners of the parent
¥200 million
Target fiscal yearFY2025
Advanced research and development support businessRevenue growth of at least 7% per year on average
Healthcare solutions businessDevelop the business into one capable of generating recurring revenue within approximately 5 years and achieve segment profitability
Market Size / Share
- Global contract metabolomics market20201932025220
- Global biomarker market20204.320259.2
- Japanese healthcare market202512.5
- Functional foods with health claims market20203,349Year on year against the same period last year+25.9%
- Domestic metabolomics market share70 Approximately %
Orders received and order backlog
Orders received
Fiscal year ended June 2019937
Fiscal year ended June 20201,172
Fiscal year ended June 2021996
Number of employees
75 People consolidated
Breakdown17 PhD holders
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ended June 2021 (full year) |
| Net Sales | ¥1,124 million (YoY +0.5%) |
| Operating profit | ¥39 million |
| Ordinary income | ¥59 million |
| Net income | ¥58 million |
| Full-year earnings forecast | Net Sales ¥1,200 million / Operating profit ¥100 million / Ordinary income ¥100 million / Profit attributable to owners of the parent ¥100 million / Earnings per share ¥16.95 |
| Segment results | Metabolomics business Net Sales ¥1,119 million / Operating profit ¥423 million / Biomarker business Net Sales ¥4 million / Operating profit ¥-70 million / Corporate and eliminations Net Sales Not disclosed / Operating profit ¥-313 million |
| Key KPIs | ¥996 million, ¥1,200 million, 9,000 papers or more, 600 papers or more, 7,000 Cases or more, 70 Approximately % |
| Number of employees | 75 People (consolidated) |
| Medium-term management plan targets | Net Sales ¥1,600 million / Profit attributable to owners of the parent ¥200 million / Advanced research and development support business Revenue growth of at least 7% per year on average / Healthcare solutions business Develop the business into one capable of generating recurring revenue within approximately 5 years and achieve segment profitability |
| Orders received and order backlog | Orders received Fiscal year ended June 2019 937 / Fiscal year ended June 2020 1,172 / Fiscal year ended June 2021 996 |
| Market Size / Share | Market Global contract metabolomics market / 2020 193 Hundreds of millions of yen / 2025 220 Hundreds of millions of yen, Market Global biomarker market / 2020 ¥4.3 trillion / 2025 ¥9.2 trillion, Market Japanese healthcare market / 2025 ¥12.5 trillion, Market Functional foods with health claims market / 2020 3,349 Hundreds of millions of yen / Year on year against the same period last year 25.9 Hundreds of millions of yen, 70 Approximately % |
| New initiatives | Expand and promote new analysis services, Launch the healthcare solutions development business, Research and development aimed at commercializing a mental health-related business, Close HMT Europe by the end of 2021 and consolidate European operations under HMT America |
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company worked to increase orders in the metabolomics business, improve sales efficiency and reduce selling, general and administrative expenses. For the fiscal year ending June 2022, it plans to expand and increase sales of new analytical offerings, improve productivity, maintain appropriate cost control, and pursue research and development in mental health-related fields.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.